The narrow-moat firm's results show that it is withstanding intense competitive and macro headwinds well, and our long-term outlook remains.
Our fair value estimate and narrow moat rating are unchanged for the firm.
The market's fixation on the wide-moat firm's near-term revenue is overshadowing its dynamic long-term cash flow model.
The wide-moat firm's core drug distribution business posted gains of 6% in results that were largely in line with expectations.
We're maintaining our fair value estimate for the wide-moat firm.
Results for the wide-moat firm beat expectations, even as the social media giant addresses data security and privacy issues.
Tesla's results were slightly ahead of expectations and we still see shares as overvalued.
McDonald's fourth-quarter update solidified our view that the firm's technology investments are having a positive impact on sales.
Cash generation was the one weak spot in firm's results, and we view shares as slightly overvalued.
As expected, the Fed didn't raise rates today, and we see signs the central bank has taken a significantly more dovish turn.
The narrow-moat firm reported solid margins, and we don't expect to change our fair value estimate.
Fourth-quarter results were a mixed bag, and we see shares as fairly valued.
We think Apple will resume mid-single-digit sales growth in fiscal 2020 despite the potential for continued weakness in China.
As the utility heads into bankruptcy, we still think shareholders won't be left empty-handed.
The wide-moat drugmaker's lower than expected 2019 guidance doesn't dent our view that the firm will be bolstered by an improving pipeline.
We're placing our fair value estimate under review after weak results from the firm's construction industries segment.
We are raising our fair value estimate for the narrow-moat firm.
The wide-moat coffee giant is one of the most attractive names in the restaurant industry today, and we see no change to our fair value estimate.
Near-term headwinds weighed on the chipmaker, but our long-term thesis is intact.
We continue to view the stock as undervalued after total sales matched expectations.
Shares of the wide-moat firm look cheap today.
Share prices are up, and we suggest investors await a more attractive entry point.
Our fair value estimate for the narrow economic moat firm is unchanged.
The wide-moat firm was leg by its drug unit, but increasing generic pressures weigh on the 2019 outlook.
The firms have agreed to expand crude oil takeaway capacity in the Rockies.
Elon Musk's plan to slim the workforce to drive down the price of the Model 3 is sensible, and our fair value estimate is unchanged.
Operating margin came in below our projections, but we are retaining our narrow moat rating and are raising our fair value estimate.
Fiserv faces an uphill battle to extract sustainable value from this deal, and we expect to adjustment to our fair value estimate downward.
The large increase in fourth-quarter net income was due to tax reform, but the strong revenue and operating income growth were due to positive trends in the company's business model and expense discipline.
The price increases are in line with the firm's need to generate additional revenue to help offset the ongoing cash burn.
We still believe the wide-moat bank has meaningful room to improve returns on equity, but it will be a bumpy ride as the bank remains under the regulatory microscope.
The narrow-moat bank is and has been firing on all cylinders.
The narrow-moat firm raised its revenue and profitability outlook for the fourth quarter.
Despite only marginal revenue growth, expenses were well-managed and allowed the bank's efficiency ratio and overall profitability to improve.
We plan to cut our fair value estimate by more than 50%, but we still believe there is positive equity value.
Optimism after analyst day sends the stock soaring, but we still think shares look cheap.
We remain positive on the firm's prospects and see an attractive margin of safety relative to our fair value estimate.
Shares of the narrow-moat firm are undervalued, but we believe Intel offers a superior opportunity.
New graphics processing unit, the RTX 2060, is well positioned for mainstream gamers.
The bankruptcy threat could be an effective strategy that preserves sizable upside.
The company showcased a bevy of promising initiatives, and patient investors may find current price levels attractive.
Earnings declines are slowing but profits remain depressed at the no-moat retailer.
Our longer-term outlook on the narrow-moat firm calls for around 6% sales growth and mid-30s operating margin on average.
The bank is currently trading at one of the highest risk adjusted discounts to our fair value estimate among the U.S. money center and regional banks.
We think the stock is undervalued, but it may remain cheap until more certainty comes in governance.
The activist investor's push for a Family Dollar divestiture could refocus resources on the better-positioned Dollar Tree banner.
Our fair value estimate remains, and we are also reaffirming our no-moat rating for the utility.
We don't expect any major changes to our fair value estimate based on the deal, with the expected revenue from acquired cancer drugs offsetting the purchase price and increased R&D expenditures.
Despite menacing headwinds for iPhone in China, the firm still can better monetize its existing user base and we see Apple shares as undervalued.
We modestly reduced our outlook for the utility as we think the a renewal of Ohio Distribution Modernization Rider is unlikely and industrial sales growth is expected to slow.